Benzinga
Benzinga
Benzinga
jueves, septiembre 24

Definium Therapeutics Inc

DFTXNASDAQ
Trade with Public
Trade with Public
$37.36
-0.29-0.77%
Últ. Act.: Sep 24, 9:27 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Definium Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Definium Therapeutics (DFTX).

Price Target Range — 3 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$64Upside to Avg. PT+70.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 15, 2026Canaccord GenuitySumant KulkarniPT RaiseBuy$64→$78
Sep 15, 2026Baird Christopher ChenPT RaiseOutperform$75→$79
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79

Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target

Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.
Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.
Avi Kapoor

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved